Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study

References

• Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018; 2018-12-0113(1):6. doi: 10.1186/s13023-017-0726-x.
   PubMed Web of Science ®Google Scholar
• Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 2013-01-018(1):31. doi: 10.1186/1750-1172-8-31.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991; Sep40(3):242–246. doi: 10.1111/j.1399-0004.1991.tb03085.x.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22(2):79–83. 2015-0403 doi: 10.3109/13506129.2014.997872.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792. 2012-08-21 doi: 10.1212/WNL.0b013e3182661eb1.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. 07/05/2018;379(1). doi: 10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023; 2023-01-0230(1):1–9. doi: 10.1080/13506129.2022.2091985.
   PubMed Web of Science ®Google Scholar
• Ueda M, Sekijima Y, Koike H, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020; 07/15/2020414:116813. doi: 10.1016/j.jns.2020.116813.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Sekijima Y. [Genetic counseling and predictive testing for hereditary neuromuscular diseases]. Rinsho Shinkeigaku. 2021; Sep 2861(9):588–593. doi: 10.5692/clinicalneurol.cn-001608.
   PubMedGoogle Scholar
• Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29 Suppl 1(Suppl 1):S27–S35. 2016-02-01 doi: 10.1097/WCO.0000000000000290.
   PubMedGoogle Scholar
• Schmidt HHJ, Barroso F, González‐Duarte A, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2016;54(3):353–360. 2016-09-01 doi: 10.1002/mus.25210.
   PubMed Web of Science ®Google Scholar
• Dohrn MF, Auer-Grumbach M, Baron R, et al. Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the german/Austrian position and review of the literature. J Neurol. 2021;268(10):3610–3625. 2021-10-01 doi: 10.1007/s00415-020-09962-6.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Reilly MM, Coats CJ, et al. Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best practice in Ireland and the UK. Adv Ther. 2022; 2022-06-039(6):2292–2301. 1 doi: 10.1007/s12325-022-02139-9.
   PubMed Web of Science ®Google Scholar
• Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019 2019;26(1):3–9. *0102 doi: 10.1080/13506129.2018.1556156.
   PubMed Web of Science ®Google Scholar
• Rozenfeld PA, Masllorens FM, Roa N, et al. Fabry pedigree analysis: a successful program for targeted genetic approach. Mol Genet Genomic Med. 2019; 2019-07-017(7):e794. doi: 10.1002/mgg3.794.
   Web of Science ®Google Scholar
• Nakamura K, Mukai S, Takezawa Y, et al. Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of fabry disease. Mol Genet Metab Rep. 2023; Sep36:100983. doi: 10.1016/j.ymgmr.2023.100983.
   PubMed Web of Science ®Google Scholar
• MacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in huntington’s disease. Clin Genet. 2013; 2013 Mar83(3):221–231. doi: 10.1111/j.1399-0004.2012.01900.x.
   PubMed Web of Science ®Google Scholar
• Crozier S, Robertson N, Dale M. The psychological impact of predictive genetic testing for huntington’s disease: a systematic review of the literature. J Genet Couns. 2015;24(1):29–39. 2015-0201 doi: 10.1007/s10897-014-9755-y.
   PubMed Web of Science ®Google Scholar
• Saraiva MJ, Costa PP, Goodman DS. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, portuguese type. J Lab Clin Med. 1983 ;Oct102(4):590–603.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Tokuda T, Kametani F, et al. Serum transthyretin monomer in patients with familial amyloid polyneuropathy. Amyloid. 2001; Dec8(4):257–262. doi: 10.3109/13506120108993822.
   PubMed Web of Science ®Google Scholar
• Jacobi H, Schaprian T, Schmitz‐Hübsch T, et al. Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset. Ann Clin Transl Neurol. 2023;10(10):1833–1843. 2023-10-01 doi: 10.1002/acn3.51875.
   PubMed Web of Science ®Google Scholar
• Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96(3):e412–e422. 2021-01-19 doi: 10.1212/WNL.0000000000011090.
   PubMed Web of Science ®Google Scholar
• Sato M, Mochizuki Y, Takahashi Y, et al. Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis. Amyloid. 2023;30(3):351–352. 2023-07-03 doi: 10.1080/13506129.2023.2187678.
   PubMed Web of Science ®Google Scholar